Illumisoft Lighting Corp. (TSXV: UVC) (OTCQB: FUVCF) has announced plans to collaborate with the Coalition for Community & Healthcare Acquired Infection Reduction (CHAIR) on a Canadian hospital research program to evaluate its SaniLume™ upper-air ultraviolet disinfection device. The program envisions 13 linked studies and facility-wide installations at sites in Manitoba and British Columbia, with studies targeted to begin in November 2026, subject to funding that has not yet been secured. Separately, the company confirmed its shares are now eligible for electronic clearing and settlement through the Depository Trust Company (DTC) in the United States. Investors may be watching the program's progress closely given the material conditions that remain outstanding.
Key Points
- Illumisoft Lighting Corp. (TSXV: UVC / OTCQB: FUVCF) announced collaboration plans with CHAIR for a Canadian hospital UV disinfection research program.
- CHAIR has signed non-binding letters of intent with health authorities in Manitoba and British Columbia for planned facility-wide SaniLume™ installations.
- The program comprises 13 linked studies; the first two are planned with the University of Waterloo, targeting a November 2026 start, subject to funding.
- Investors should watch whether program funding is secured and whether Illumisoft finalises a definitive agreement with CHAIR.
CHAIR Research Program Scope and Hospital Partners
CHAIR has entered into non-binding letters of intent with Shared Health and Winnipeg's Health Sciences Centre in Manitoba, and with the Provincial Health Services Authority in British Columbia, for planned facility-wide SaniLume™ installations. The program is designed to measure the device's effect on airborne pathogens, surface contamination, and transmission of respiratory viral illness across 13 linked studies. The first two studies, in partnership with the University of Waterloo, will include a bioaerosol chamber study and a computational fluid dynamics study of air movement in clinical spaces.
Illumisoft's Role and Outstanding Conditions
Under the proposed agreement, Illumisoft would supply SaniLume™ units for the planned installations and studies. The company has disclosed that the number of units, pricing, and other terms have not yet been finalised. Critically, Illumisoft is not a party to the letters of intent, has received no purchase orders connected to the program, and does not control the program or its timing. The company explicitly cautioned that there is no assurance the program will be funded, that installations or studies will proceed, or that a definitive agreement will be reached.
SaniLume™ Laboratory Performance and Health Canada Licensing
SaniLume™ is a Health Canada-licensed, fan-assisted upper-air UV device manufactured by Illumisoft in Ottawa. In chamber testing at the University of Leeds, reported in August 2022 and commissioned by Illumisoft, the device reduced airborne concentrations of test organisms by between 97% and 99.7%, depending on organism and device setting. The company noted that laboratory results do not establish performance in clinical settings, which the proposed research program is specifically intended to evaluate.
DTC Eligibility Enhances U.S. Market Access for Illumisoft Shares
Illumisoft also announced that its common shares are now eligible for electronic clearing and settlement in the United States through the Depository Trust Company. The company stated that DTC eligibility is expected to simplify trading and enhance share liquidity for U.S. investors. Illumisoft shares trade on the TSX Venture Exchange under the symbol UVC and on the OTCQB® Venture Market under the symbol FUVCF.



Please wait processing your request...